Usefulness of Therapeutic Drug Monitoring and Pharmacogenetics for a Patient Treated with Olanzapine, Buspirone, and Fluvoxamine: A Case Study

作者：Jing Ding, Jing Yang, Yan Zhang, Zhuocheng Meng, Ren Jianli, Suo Zhang, Jiarui Liu, Xiaohua Cui · 发表于：Therapeutic Drug Monitoring · 年份：2023 · DOI：10.1097/ftd.0000000000001093 · 被引用次数：1 · 研究领域：Schizophrenia research and treatment、Treatment of Major Depression、Pharmacogenetics and Drug Metabolism

BACKGROUND: A patient, with a mental disorder caused by an intracranial infection, treated with olanzapine, fluvoxamine, and buspirone. The plasma exposure of olanzapine was too high at standard doses, with evidence indicating that it was caused by drug-drug interactions. METHODS: Using pharmacogenomics and therapeutic drug monitoring to guide drug dose adjustment for a patient in clinical practice. RESULTS: The patient underwent pharmacogenetic testing in addition to therapeutic drug monitoring as part of a pharmacist-led comprehensive evaluation of medication therapy management in a clinical setting, resulting in improved clinical efficacy that allowed discharge from a psychiatric hospital. CONCLUSIONS: This case study demonstrates that therapeutic drug monitoring combined with pharmacogenetic-guided dose adjustment can aid in the management of patients receiving complex pharmacological treatments.